Ryan Garcia left no doubt. After a heated build-up between two of boxing's biggest names, the reigning WBC welterweight champion delivered a devastating performance Saturday night inside of Las Vegas' T-Mobile Arena, needing less than two rounds to dispatch Conor Benn and successfully defend his belt in a statement performance.
After controlling the opening round, Garcia ended matters in spectacular fashion early in the second, uncorking a massive right hand that sent Benn crumbling to the canvas. Benn managed to beat the 10-count, but Garcia immediately swarmed his wounded prey and unloaded against the ropes until the referee mercifully stepped in to stop the bout.
Afterward, Garcia (26-2, 21 KOs) called for WBA welterweight champion Teofimo Lopez to join him in the ring, teasing the possiblitiy of a massive unification clash next. Benn (25-2, 14 KOs), meanwhile, suffered the first stoppage loss of his pro career.
Unsurprisingly, as is often the case with anything Garcia does, Saturday's result instantly set the boxing world ablaze, prompting a flood of fellow fighters to gush over Garcia's spectacular performance on social media — and eliciting a healthy amount of revelry from Benn's critics. Chief among those critics was Chris Eubank Jr., who couldn't help but chime in with a roast of his longtime rival following their two-fight series in 2025.
Welcome to the ’fighting after cutting too much weight’ club… Enjoy

#welterweight #ryan

On August 13, a federal appeals court ruled in favor of Gilead Sciences, Inc. (NASDAQ:GILD), upholding a preliminary injunction that bars the defendants from importing or facilitating the sale of foreign-market Gilead-branded medications in the US. The US Court of Appeals for the Fourth Circuit found that the differences between Gilead's HIV medication for the US market and the foreign versions being imported were "material, not theoretical." The controversy began in December 2024 when Gilead Sciences, Inc. (NASDAQ:GILD) filed suit against a number of companies, including third-party administrator Meritain Health, pharmacy benefit manager ProAct, and pharmacies Rx Valet and Advanced Pharmacy, alleging illegal imports of its best-selling HIV drug Biktarvy.
The dispute dates back to December 2024, when Gilead Sciences, Inc. (NASDAQ:GILD) sued a group of companies, including third-party administrator Meritain Health, pharmacy benefit manager ProAct, and pharmacies Rx Valet and Advanced Pharmacy, alleging illegal imports of its top-selling HIV drug Biktarvy. The lawsuit arose from a specific instance in which a patient in Maryland received the medicine in the mail from Turkey, with label instructions written in Turkish.
A federal district court in Baltimore ruled in Gilead's favor and ordered a preliminary injunction, determining that the company was likely to succeed on its Lanham Act trademark violation and unfair competition arguments. As the case continued, the injunction was increased to include new sellers like CanaRx, ElectRx, and ScriptSourcing. The defendants filed an appeal with the Fourth Circuit, and the district judge declined to suspend the injunction while the appeal was pending, thus the import restriction has been in effect the entire time. The recent ruling maintains the order rather than overturning it.
In court documents, Rx Valet stated that the Turkish-sourced Biktarvy was chemically identical to the US version, which was offered at a significantly higher price. Meritain, for its part, said that it has never supported getting non-FDA-approved pharmaceuticals from outside the US and denies the claims, despite being named as a defendant.
The Fourth Circuit rejected the defendants' main argument that the imported and domestic versions of Biktarvy are interchangeable. The court's judgment that the two versions differ materially, not just in packaging or labeling, but also in the quality-control protocols that each version goes through before reaching a patient, challenges the basic argument that these alternative funding programs have used to support their business model.

#gild

EAST LANSING — Michigan State coach Pat Fitzgerald thinks he may have his most important defensive player back for next week's game against Notre Dame.
In his postgame press conference after a 35-7 win over Eastern Michigan on Saturday, Sept. 12, Fitzgerald said that starting middle linebacker Jordan Hall was not cleared for the game by medical personnel but could be available for Week 3's rivalry game in South Bend.
"Jordan was really close playing today," Fitzgerald said. "Medical team told us that he was not cleared here late in the week. We made that decision collectively together to make sure that we think about his health, safety, and well-being. And I expect if we practice tomorrow that he'll be ready to go."
Hall made 88 tackles last season to lead Michigan State's defense and is a two-time captain. The senior made four tackles in 25 snaps in Week 1's win over Toledo but came on and off the field with a right elbow injury sustained on the second drive of the season. He walked into Spartan Stadium on Saturday with a brace on that right arm.
MSU LB Jordan Hall with a brace on his right elbow as he takes the Spartan Walk.

Saw him wince on a couple of handshakes. We’ll see how he looks in warmups.detroitnews pic.twitter.com/qklOKEfVbs

#game #spartan

Restaurant stock Dave & Buster's Entertainment (PLAY) and healthcare name Kestra Medical Technologies (KMTS) will kick off earnings reports during a week when investors will be squarely focused on the Federal Reserve and a possible interest-rate hike Wednesday. Forgent Power Solutions (FPS) is also on the docket, with its stock trying to recover after a lengthy sell-off.
Friday's stock market rally notwithstanding, the Dow Jones Industrial Average and the Russell 2000 small-cap index have come under the most pressure amid surging oil prices and spiking bond yields, as investors worry about pesky inflation and escalating tension between the U.S. and Iran.
While the Dow is testing major support near 52,000, the Russell fell below its 50-day moving average in late August and has been below the support level ever since. The Nasdaq composite, meanwhile, bounced off its 50-day line with conviction Friday, helped by a tame report on consumer prices. The S&P 500 also moved off its 50-day line Friday.
Results from Lennar (LEN) are due Wednesday after the close. Lennar stock tried to break out in late June, but was turned away at its 200-day line and went into a downtrend. It tried to clear the 200-day line several times again in August but to no avail. With interest rates on the rise, heavy-volume selling has picked up the pace in recent weeks.
Forgent, which sells electrical distribution equipment to data centers, reports early Tuesday. The company priced its IPO at 27 on Feb. 4, at the midpoint of a proposed range of 25-29.

#line #forgent #august #lennar

On September 8, a caller inquired if Trinity Industries, Inc. (NYSE:TRN) is worth looking at after its recent pullback. Mad Money host Jim Cramer replied:
Yes, Railcar, shouldn't be down this much. I like your thinking. You waited for the big hit. Now, it's in a good place. I would pull the trigger.
Trinity Industries, Inc. (NYSE:TRN) has faced a sharp correction, pulling back significantly from its 52-week high of $38.31. Despite this downward pressure, the company's fundamental **** et base remains exceptionally stable. In its second-quarter earnings report, the company posted total revenues of $485 million and diluted earnings per share from continuing operations of $1.25, with earnings benefiting from a $132 million non-cash pre-tax gain tied to the Napier Park railcar partnership transaction.
The leasing and services segment continues to support the business, posting a robust fleet utilization rate of 97.3% and an improved lease renewal success rate of 75%. In addition, the Future Lease Rate Differential improved to +3.5%, showing healthy pricing power on expiring contracts. Management reaffirmed its full-year EPS guidance of $2.20 to $2.40, supported by a solid railcar backlog standing at $1.6 billion.
The primary catalyst for Trinity Industries, Inc.'s (NYSE:TRN) recent sell-off stems from margin compression within the Rail Products manufacturing division. Operating margins in manufacturing faced pressure from an unplanned production interruption at the Longview manufacturing facility and temporary realignment expenses tied to the company's Mexican footprint. These localized execution issues overshadowed a strong quarterly performance in leasing, causing the stock to drift below both its 50-day and 200-day moving average.

#trinity

To summarize my investment approach, I prefer to buy companies with long histories of dividend increases and historically high yields. Those two traits don't come around all that often, and sometimes I find clusters of stocks in specific sectors. I need to think specifically about diversification, one of the simplest and most effective ways to reduce risk. Here's how I've done it as I've built my portfolio of around 34 investments.
The Motley Fool recommends that investors own 50 stocks. That's a perfectly fine number, but also a lot of work. And just owning 50 stocks doesn't actually mean you are diversified. You could own 50 technology stocks, for example, which would leave you with exposure to just a single sector. That's not diversification. Diversification is really about owning a reasonable number of investments across a wide range of sectors and ****** et classes.
Missed Nvidia in 2009? This Rare Signal Is Flashing Again. In 2009, a "Double Down" signal flashed for a little-known chipmaker called Nvidia. For the first time in years, that same "Total Conviction" signal is flashing for a company 1/100th the size of Nvidia. Continue »
My first step toward diversification was to take an honest look at what I want to achieve and what I'm capable of. My goal is a mixture of income and capital appreciation. I am fairly confident in my ability to select dividend stocks, though every investor makes mistakes from time to time, and I know I can only juggle so many stocks at once. In other words, 50 stocks are too many for me, so a core part of my diversification strategy is to outsource some of my work.
For example, I own two Baron mutual funds to gain exposure to growth stocks and smaller companies. I own several closed-end funds: one focused on healthcare stocks with an option income overlay, one investing in convertible securities, and one with a broadly diversified dividend portfolio. And I own three exchange-traded funds: one with an option income focus and two that use very different screening approaches to pick dividend stocks.

#Diversification #funds

New England Patriots coach Mike Vrabel doesn't have any regrets about his decision to rest the starters during the three-game preseason slate.
However, it was clear that the team showed rust in Wednesday's 13-10 loss to the Seattle Seahawks, particularly on the offensive side of the ball. Vrabel opted to use the preseason to focus on the roster depth and preserve the health of the starters.
That's a decision that he continued to defend after the disappointing loss in the season opener.
"Playing the backups for the Eagles or the Colts for eight plays, I don't think was going to prepare us for what we saw last night," Vrabel told media members. "I thought we handled the environment; I thought we did. I know the execution wasn't good enough, but the line of scrimmage, penalties, the operation, those things gave us a chance. Some other things didn't give us a chance."
Mike Vrabel on if he regrets not playing any Patriots starters in the preseason.

"Playing the backups of the Eagles or Colts for eight plays I don't think was going to prepare us for what we saw last night." pic.twitter.com/L1efdmrmsk

#starters #colts #regrets

Arsenal made it four wins from four in the Premier League with a hard-fought 2-0 win over Sunderland at the Stadium of Light. The Black Cats played a gritty, physical game, but the Gunners gave as good as they got, and battled to the win. With a massive ***** ist from David Raya saving a, uh, generously awarded penalty that would have made it 1-0 for the bad guys. Minutes later, Bruno Guimaraes put one top bins. Raya made another brilliant save later in the half. Deep in added time, Bruno put Bukayo Saka in on goal, earning a penalty and second yellow to Reinildo. Penalty converted. Game over.
The Sunderland crowd greeted Bruno with a chorus of boos when he replaced Myles Lewis-Skelly at halftime. They take their rivalry with Newcastle seriously. Unfortunately, it was very much a "keep booing, it only makes me stronger" moment. You could see from the little smile on Bruno's face that he was loving it and using it to fuel him. His "I can't hear you" celebration to the crowd after he'd put one on postage stamp was absolute perfection.
Great call from Mikel Arteta to pull Myles Lewis-Skelly at the break. Everything was off from him — poor touches, cheap fouls — it simply wasn't his night. The manager also had to swap Jurrien Timber for Ben White, who appeared to have tweaked his groin. Because when ***** nal get one right back healthy, the other gets injured. That's how it works. Timber was excellent, by the way.
The ***** nal subs that came on later in the second half, Eze, Merino, and Zubimendi, were mediocre to poor. The depth is tremendous but Mikel Arteta has his work cut out for him to keep everyone sharp so that when they are called into action they don't, say, give the ball away the only two times they get on it like Merino did today.
The Gunners could have and should have been ahead at halftime, but once again, they were profligate with scoring chances. Bukayo Saka was caught in two minds on a leaping volley and only managed glancing contact. Kai Havertz shot over the bar from in close. The German striker also forced a smart save with a brilliant control, turn, and volley move. Saka also flubbed two chances in the second half — he picked the wrong pass on a 4-on-2 break and he shot too close to the keeper. The side could do with a bit better finishing, but if you believe (as I generally do) that finishing ebbs and flows, as long as they keep generated the volume of chances, someone is in for a real hiding.

#second

SACRAMENTO, Calif. (AP) — The California labor leader behind a proposal to tax billionaires has been accused of harassing and intimidating several women who work for an affiliated union.
The allegations against Dave Regan, president of the SEIU United Healthcare Workers West, are detailed in an investigative report commissioned by SEIU California and obtained Friday by The ******* ociated Press. It includes interviews with several current and former SEIU members and others who say Regan tried to intimidate union leaders into supporting the billionaires' tax, which goes before voters in November.
The Los Angeles Times was the first to report on the allegations.
The report also includes allegations that Regan physically ******* aulted an SEIU leader more than 15 years ago amid a political dispute and that more recently he engaged in harassing behavior against other women who work for the organization.
Regan acknowledged using curse words with union leaders but denied the physical ******* ault allegation.

#regan #seiu #report #harassing

On September 3, Genesco (NYSE:GCO) reported a second quarter that should not have worked on paper. Revenue fell 3% to $530 million, yet the company nearly halved its adjusted operating loss and raised full-year earnings guidance to the top end of its range. That combination, shrinking sales alongside expanding profit, is the footwear-first strategy showing up in real numbers. Every one of the company's three brands beat internal expectations, and management says the toughest sales pressure ahead is coming from a deliberate choice rather than a weakening business.
Journeys, the company's teen-focused chain, delivered its eighth consecutive quarter of positive comparable sales, up 2%, even while lapping strong growth from a year earlier. The more interesting story sits underneath that number. The Journeys 4.0 store format, a redesigned concept built around a more elevated ***** ortment, is generating a sales lift of 25% or more wherever it opens, and the company expects roughly 180 locations, about a fifth of its fleet, running that format by year-end. That rollout, combined with fleet optimization and more efficient use of selling staff, handed Journeys 180 basis points of expense leverage in the quarter. Comparable sales kept accelerating into August, marking Journeys' ninth straight month of positive comps and a mid-single-digit gain during the back-to-school peak.
Johnston & Murphy is running its own streak, with comparable sales up 4% in its third consecutive positive quarter, helped by a newly extended, multiyear partnership with Peyton Manning and a broader shift in menswear toward more refined, put-together dressing. Companywide, adjusted gross margin expanded 140 basis points to 47.2%, and the adjusted operating loss narrowed to $8 million from $14 million a year ago. Genesco also collected $22.5 million in tariff refunds during the quarter and cut total debt to $15.8 million from $71 million a year earlier, giving a new CFO and a new Schuh president a far healthier balance sheet to work with as they settle into their roles.
The drag comes almost entirely from Schuh, Genesco's UK chain, where comparable sales fell 9% as management deliberately pulled back on discounting to protect margin. Executives were blunt about the cost of that choice. CEO Mimi Vaughn said "the UK consumer market remains challenged and price sensitive," and the Schuh turnaround is expected to take longer than the one already underway at Journeys. That pressure is now baked into guidance. Full-year total sales are expected to fall about 2%, worse than the prior forecast of down 1% to flat, with management incorporating more back-half sales pressure than it originally planned for given how promotional the UK footwear market has become.

#comparable #schuh #management #pressure

The New England Patriots may need to address their edge rusher unit after another injury landed on Harold Landry's doorstep to begin the 2026 NFL season.
The Patriots have a productive unit when healthy, led by Landry and Dre'Mont Jones, with rookie Gabe Jacas expected to produce meaningfully for the team. However, more may be needed.
Bleacher Report's Kristopher Knox labeled Maxx Crosby and Kayvon Thibodeaux as being two star edge rushers that the Patriots ought to trade for in 2026, in the event that they pursue a player to fill their needs in the trade market.
"If another team comes calling about Crosby, the Raiders will undoubtedly listen," Knox said. "They're in the early stages of a rebuild and may not be ready to contend while Crosby is still in his playing prime. The asking price will be high, but teams that believe they can chase a Super Bowl are bound to target him before November 10."
Crosby is a superstar edge rusher who has the talent to take New England over the top in the Super Bowl race. Giving up draft picks and a player or two will do the Patriots much good to stack their roster with Drake Maye, A.J. Brown, Christian Gonzalez, Romeo Doubs and Crosby as the heaviest-hitters on their team.

#super

LSU football faces Louisiana Tech on Saturday night in what should be a tune-up game for the Tigers, though not much tuning is needed after LSU beat Clemson 51-10 in Week 1.
LSU is a heavy favorite vs. the Bulldogs. Last week, LSU's second team got plenty of reps in a lopsided victory, and the depth chart could be emptied again today. If LSU starts fast and builds a healthy lead in the first half, a handful of true freshmen will get significant time in the second half.
The SEC schedule is a grind. And in the era of the 12-team playoff and extended seasons, developing depth can be the difference between missing the College Football Playoff or going on a run. LSU has the raw talent to make noise in Lane Kiffin's first year, but LSU will need some young guys to step up.
Here are four true freshmen to watch when LSU football takes on Louisiana Tech.
Lamar Brown was the headline piece of Lane Kiffin's first high school signing class. ESPN ranked Brown as the No. 1 overall recruit in the country and he was heralded as a player ready to make an immediate impact, despite not enrolling early.

#first #louisiana #Tech #brown

Baker Mayfield gets dangerous weapon back ahead of Bengals clash originally appeared on The Sporting News. Add The Sporting News as a Preferred Source by clicking here.
Tampa Bay Buccaneers wide receiver Emeka Egbuka appears ready to go for Week 1 after a toe injury created some uncertainty around his status during the preseason.
Egbuka returned to full practice this week and is expected to play when Tampa Bay takes on the Cincinnati Bengals, giving quarterback Baker Mayfield one of his most dangerous weapons for a matchup that has the potential to become a high-scoring affair.
The second-year receiver enters the season with plenty of expectations after showing flashes of becoming a legitimate No. 1 option early in his rookie campaign.
Egbuka demonstrated his ability to create separation, make plays after the catch and stretch defenses before injuries became a factor. His own health issues, combined with injuries affecting Mayfield, prevented Tampa Bay from consistently taking advantage of the chemistry the two displayed earlier in the season.

#tampa

The Buffalo Bills will open the 2026 NFL season in a place where they have struggled to find success in recent years: on the road against the Houston Texans, who boast one of the league's stingiest defenses.
Since coming to the Bills as the No. 7 overall pick in the 2018 NFL Draft, Josh Allen has led the Bills into Houston four times. And in all four prior matchups, the Bills couldn't pull out the win.
Sunday will mark the third consecutive season where Buffalo has traveled to Houston, and today's edition of Buffalo Rumblinks leads off by sharing the key matchups to watch and positional ***** ysis as the Bills look to snap that streak and begin the season with a big road win over a fellow playoff participant from last season.
Check out the ***** sments below and then let us know your thoughts on the game in the comments section.
Linked below: Breaking down the key story lines to watch, including dissecting the approach new defensive coordinator Jim Leonhard will take to contain the Texans; how Joe Brady can better position Josh Allen and the offense for success against a Texans pass rush that sacked Allen eight times in last year's loss; why starting right tackle Spencer Brown thinks things will go much differently against Will Anderson and Danielle Hunter, two of the game's premier pass rushers, now that both Brown and starting left tackle Dion Dawkins are fully healthy; how Greg Rousseau and Bradley Chubb need to generate more pressure on Texans QB CJ Stroud than the Bills have their last two trips to Houston (one total sack); and more!

#last

After examining the Jacksonville Jaguars' final injury report of Week 1, where do the Cleveland Browns stand health-wise entering this game?
On Friday afternoon, the Browns ruled out guard Teven Jenkins (back) and listed center Parker Brailsford (thumb) as questionable.
Jenkins made four starts last year in his first season with Cleveland and was slated to start at right guard in 2026. Expected to start in Jenkins' place is rookie Austin Barber -- a third-round pick by the Browns.
Andrew Harbaugh of Browns Wire recently provided some insight into what Barber can bring to the Browns' offensive line unit:
"Barber didn't play guard at Florida, so it's a new position for him after logging 2,087 snaps at left tackle and 490 snaps at right tackle during his time with the Gators," wrote Harbaugh. "He brings a nasty temperament to the run game, looking to finish guys by blocking them into the dirt."

#harbaugh #start #right #snaps

After examining the Indianapolis Colts' final injury report of Week 1, where do the Baltimore Ravens stand health-wise entering this game?
On Friday afternoon, the Ravens ruled two players out -- defensive tackle Nnamdi Madubuike (neck) and linebacker Teddye Buchanan (knee).
Game status at Colts pic.twitter.com/5qgFJw1YN3
Glenn Erby of Ravens Wire provided some insight into what Madubuike's absence could mean for this game:
"Madubuike's absence leaves Baltimore without its most disruptive interior pass rusher for a matchup," Erby wrote. "His ability to collapse the pocket and create penetration against the run would have been valuable against one of the NFL's most explosive running backs."

#erby

The Indianapolis Colts open the regular season at home against the Baltimore Ravens.
To help us preview this matchup, Glenn Erby, the managing editor of Ravens Wire, answered a handful of our questions to provide some insights into this Baltimore team.
Ravens Wire: Minter has been organized, direct, and consistent since taking over. He brings energy without manufacturing it, and players have responded to his detailed but collaborative approach. He has also allowed his coordinators to establish their identities while remaining heavily involved with the defense. The biggest takeaway is that he appears comfortable leading the entire operation rather than simply functioning as a defensive-minded head coach. The regular season will present different challenges, but the transition from John Harbaugh has been smoother than many expected.
Ravens Wire: Baltimore's defensive front should be its biggest strength. The Ravens added Trey Hendrickson to a group that could regain Nnamdi Madubuike while also featuring Calais Campbell, Travis Jones, and second-round pick Zion Young. Roquan Smith and Kyle Hamilton give the defense elite talent behind that front. If Madubuike remains healthy, Baltimore should be able to stop the run without sacrificing its ability to pressure quarterbacks.
Ravens Wire: The interior offensive line is the primary concern. Baltimore will start Jovaughn Gwyn at center and rookie first-round pick Vega Ioane at right guard. Gwyn has never started an NFL game, while Ioane will make his regular-season debut against DeForest Buckner and Grover Stewart. The Ravens are also installing Declan Doyle's offense, so communication and protection errors could occur early. Lamar Jackson and Derrick Henry can cover plenty of weaknesses, but Indianapolis has the personnel to test that inexperienced interior.

#Ravens

Washington hosts Utah State tomorrow but before we transition to Saturday's gameday coverage. Here is the Week 1 mailbag!
Chicken Little: Is it time to panic?
I wouldn't say the sky is falling, but there is certainly plenty of reason to be concerned. The Huskies' struggles on offense are excusable, but they make you seriously consider a complete shift in expectations now that their two best running backs will miss time. Washington is in desperate need of a hot start to stay as healthy as possible for the toughest games on the schedule, which come in the second half of the season. I get that rivalry games can be funky, but there is zero reason why the Apple Cup should've been as close as it was. Wazzu's offense was horrid, and Washington's was equally so until the fourth quarter. For a team wanting to compete with the Big Ten elite… that's bad. I'm not panicking just yet, but I am considering lowering my win total because I'm not sure if UW will be healthy enough to be the best version of itself.
iadawg: Ellinneus Davis was supposed to be the best defensive lineman but he only had the third most snaps of defensive linemen. Can you explain this? Thanks.
Definitely strange, but I wouldn't spend too much time thinking about it unless it happens against Utah State and Eastern Washington. There's a good chance he had a minor injury bugging him, or head coach Jedd Fisch and defensive coordinator Ryan Walters saw opportunities with other lineman and took advantage. In the end, it worked out for the Huskies. His lower-than-expected usage rate is not a trend that I think will continue through the remainder of September.

#washington #time #defensive #offense

Horizon Technology Finance Corp., an affiliate of Monroe Capital, on September 10 said that the RoHo Capital Opportunity Fund LLC, a joint venture formed by Horizon and CR Financial Holdings, Inc., the holding company for Roth Capital Partners, LLC, has provided a $20-million senior credit facility to NeoVolta, Inc., with the ability to increase the facility to $30 million upon mutual agreement. An initial $20 million was funded at closing to support NeoVolta's continued growth.NeoVolta is an energy technology company focused on developing and manufacturing domestic battery energy storage systems (BESS). Together with its joint venture partner LONGi, NeoVolta is developing a 210,600-square-foot manufacturing facility in Pendergrass, Georgia, to produce BESS systems designed to meet U.S. domestic content and supply-chain requirements. The facility is expected to have an initial annual production capacity of up to 2 GWh, with the potential to scale to 8 GWh over time."Providing growth capital to innovative companies operating in attractive, high-growth markets is a core focus of RoHo's investment strategy," said Paul Seitz, chief investment officer of Horizon. "Formed by Horizon and Roth Capital, RoHo pairs Horizon's venture lending and structuring expertise with Roth's deep public markets relationships to deliver flexible growth capital to small- and micro-cap public companies. We are pleased to support NeoVolta's growth plans with a tailored financing solution and look forward to continuing to deploy capital through RoHo in support of innovative public companies pursuing significant market opportunities.""Horizon and Roth Capital bring valuable experience and a collaborative approach as we advance NeoVolta's domestic battery energy storage systems manufacturing platform," said Ardes Johnson, CEO of NeoVolta. "As we ramp our Georgia facility and pursue larger commercial and utility-scale opportunities, this relationship supports our ability to execute on our long-term growth strategy."Horizon Technology Finance Corp. is a specialty finance company that provides capital in the form of secured loans to venture capital and private equity-backed companies and publicly traded companies in the technology, life science, healthcare information and services, and sustainability industries. The investment objective of Horizon is to maximize its investment portfolio's return by generating current income from the debt investments it makes and capital appreciation from the warrants it receives when making such debt investments. Horizon is headquartered in Farmington, Connecticut, with a regional office in Pleasanton, California, and investment professionals located throughout the U.S.Monroe Capital is a premier ****** et management firm specializing in private credit markets across various strategies, including direct lending, technology finance, venture debt, opportunistic, structured credit, real estate and equity.CR Financial Holdings, Inc., is a private hol

Annual U.S. cancer deaths tied to alcohol consumption more than doubled over a three-decade period, according to a recent study led by researchers at the Sylvester Comprehensive Cancer Center at the University of Miami Miller School of Medicine.
The findings, published in The Lancet Regional Health — Americas and presented at the American Society of Clinical Oncology Annual Meeting in Chicago, revealed that alcohol-attributable cancer deaths jumped from 11,361 in 1990 to 23,126 in 2023.
Researchers ******* yzed more than 30 years of data from the Global Burden of Disease study to track the trends.
Beer, Wine Or Liquor? Massive Study Reveals Which Was Linked To Lower Death Risk
While alcohol has long been classified as a Group 1 carcinogen by the International Agency for Research on Cancer, surveys show that awareness of its link to cancer remains limited.

#study

Saint Louis, Missouri-based Centene Corporation (CNC) operates as a healthcare enterprise that provides programs and services to underinsured and uninsured families and commercial organizations in the United States. The company has a market capitalization of $31.6 billion and operates through Medicaid, Medicare, Commercial, and Other segments.
Companies with a market cap of $10 billion or more are typically called "large-cap stocks." CNC fits squarely into that category, with a market cap above this threshold that reflects its substantial size and influence in the healthcare plans industry.
'Not Tens Of Billions, But Tens Of Trillions': Nvidia CEO Jensen Huang Says AI Is Like the New Electricity and the Scale Is Unlike Any Tech in History
What It Means for MSFT Stock Investors as Microsoft Switches to 2 Business Segments
RKLB Stock Jumps as Rocket Lab Debuts New Solar Cell for ****** e

#saint

Alix Earle and her sister, Ashtin, are urging women to take proactive control of their health after learning they both carry a BRCA gene mutation.
The news arrived shortly after their mom, Alisa, was diagnosed with breast cancer in late 2025 and subsequently tested positive for the BRCA2 mutation.
More from SheKnows
Stella Parton Reveals the Real Reason Why Dolly Kept Her Cancer Battle Private
The family documented the emotional moment the sisters received their test results during their Netflix docuseries, Earle Meets World.

#brca

Durham, North Carolina-based IQVIA Holdings Inc. (IQV) provides healthcare research services. Valued at $42.3 billion by market cap, the company offers ******* ytics, technology solutions, and clinical research services to the life sciences industry which helps them in the clinical development and commercialization of medical treatments that improve healthcare outcomes for patients.
Companies worth $10 billion or more are generally described as "large-cap stocks," and IQV perfectly fits that description, with its market cap exceeding this mark, underscoring its size, influence, and dominance within the diagnostics & research industry. With strong revenue growth and a global presence in over 100 countries, IQVIA's expertise and scale provide a competitive edge that is hard to replicate.
'Not Tens Of Billions, But Tens Of Trillions': Nvidia CEO Jensen Huang Says AI Is Like the New Electricity and the Scale Is Unlike Any Tech in History
What It Means for MSFT Stock Investors as Microsoft Switches to 2 Business Segments
RKLB Stock Jumps as Rocket Lab Debuts New Solar Cell for ******* e

#Research #Stock #healthcare

Prosper Stars & Stripes, a long/short equity fund, recently released its second-quarter 2026 investor letter. The letter can be downloaded here. In Q2 2026, the portfolio delivered a strong net return of +30.1% compared to the Russell 2000 Index's +21.5% return and the HFRX Equity Hedge Index's +10.3% return. The long book drove performance, generating a 43.2% gross contribution, while average net exposure remained relatively modest at 47%. U.S. economic growth remained resilient despite inflation concerns, elevated energy prices, and geopolitical uncertainty. Markets rallied sharply after easing U.S.-Iran tensions pushed oil prices lower, supporting renewed risk appetite. Small-cap equities benefited significantly, with Information Technology, Industrials, and Health Care leading gains, while Energy declined as crude prices fell. Year to date, the Composite returned +23.7%, slightly ahead of the Russell 2000's +22.6% and well above the HFRI Equity Hedge Index's +9.7%. Additionally, you can review the Portfolio's top 5 holdings to see its best picks for 2026.
In its second-quarter 2026 investor letter, Prosper Stars & Stripes highlighted TechTarget, Inc. (NASDAQ:TTGT) as the largest contributor to the portfolio's short book. TechTarget, Inc. (NASDAQ:TTGT) provides sales and support of purchase intent-driven advertising campaigns. On September 9, 2026, TechTarget, Inc. (NASDAQ:TTGT) closed at $3.89 per share. Over the past month, TechTarget, Inc. (NASDAQ:TTGT) returned 1.57% and its shares lost 35.17% over the past 52 weeks. TechTarget, Inc. (NASDAQ:TTGT) has a market capitalization of $281.37 million, and its stock has traded within a 52-week range of $3.37 to $7.15.
Prosper Stars & Stripes stated the following regarding TechTarget, Inc. (NASDAQ:TTGT) in its Q2 2026 investor letter:
"TechTarget, Inc. (NASDAQ:TTGT) was the largest contributor to our short book during the quarter. The company monetizes the purchase research behavior of enterprise IT buyers by operating a network of websites where buyers register to consume technical content, then selling those intent signals as leads to IT vendors. We first shorted the company after it completed a value-destroying acquisition in December 2024 that led to significant impairment charges in Q1 2025 and again in Q1 2026. We believe AI is likely to dismantle search-based discovery and commoditize content, the two pillars of TechTarget's value propositions. Results have validated our concerns, with management describing its market as mature, with 2% to 3% top-line growth, and EBITDA margins that peaked in 2022 falling to 7% in Q1 2026. Notably, revenue growth began deteriorating before ChatGPT launched in November 2022, suggesting that problems run deeper than AI alone. We continue to believe generative AI will weigh on TechTarget's prospects and remain short the company."

#techtarget #NASDAQ

Prosper Stars & Stripes, a long/short equity fund, recently released its second-quarter 2026 investor letter. The letter can be downloaded here. In Q2 2026, the portfolio delivered a strong net return of +30.1% compared to the Russell 2000 Index's +21.5% return and the HFRX Equity Hedge Index's +10.3% return. The long book drove performance, generating a 43.2% gross contribution, while average net exposure remained relatively modest at 47%. U.S. economic growth remained resilient despite inflation concerns, elevated energy prices, and geopolitical uncertainty. Markets rallied sharply after easing U.S.-Iran tensions pushed oil prices lower, supporting renewed risk appetite. Small-cap equities benefited significantly, with Information Technology, Industrials, and Health Care leading gains, while Energy declined as crude prices fell. Year to date, the Composite returned +23.7%, slightly ahead of the Russell 2000's +22.6% and well above the HFRI Equity Hedge Index's +9.7%. Additionally, you can review the Portfolio's top 5 holdings to see its best picks for 2026.
In its second-quarter 2026 investor letter, Prosper Stars & Stripes highlighted Ambiq Micro, Inc. (NYSE:AMBQ). Ambiq Micro, Inc. (NYSE:AMBQ), provides ultra-low-power semiconductor solutions, contributed to the portfolio's long book during the quarter. On September 09, 2026, Ambiq Micro, Inc. (NYSE:AMBQ) closed at $63.78 per share. Over the past quarter, Ambiq Micro, Inc. (NYSE:AMBQ) declined 0.89% and its shares gained 74.38% over the past 52 weeks. Ambiq Micro, Inc. (NYSE:AMBQ) has a market capitalization of $1.53 billion, and its stock has traded within a 52-week range of $22.12 to $91.61.
Prosper Stars & Stripes stated the following regarding Ambiq Micro, Inc. (NYSE:AMBQ) in its Q2 2026 investor letter:
"Ambiq Micro, Inc. (NYSE:AMBQ) was the second-best contributor to our long book during the quarter. Ambiq is a fabless semiconductor company that designs ultra-low power systems-on-chip (SoCs) for edge AI applications. The company's proprietary design approach delivers two to five times lower power consumption than competing solutions, a decisive advantage in battery-constrained devices like wearables, where customers include Garmin, Google, and Huawei. In semiconductors, we look for companies levered to two enduring themes: lower power consumption and miniaturization. In January, the company raised equity, signaling a step-change in revenue growth. After posting 2% year-over-year revenue growth in Q4 2025, the company reported 59% growth in Q1 2026 and guided for 75% growth for Q2. We ascribed a high single digit multiple of sales to the shares, but as the price met our bullish targets, like many stocks in this part of the market, we exited our position."

#micro

Prosper Stars & Stripes, a long/short equity fund, recently released its second-quarter 2026 investor letter. The letter can be downloaded here. In Q2 2026, the portfolio delivered a strong net return of +30.1% compared to the Russell 2000 Index's +21.5% return and the HFRX Equity Hedge Index's +10.3% return. The long book drove performance, generating a 43.2% gross contribution, while average net exposure remained relatively modest at 47%. U.S. economic growth remained resilient despite inflation concerns, elevated energy prices, and geopolitical uncertainty. Markets rallied sharply after easing U.S.-Iran tensions pushed oil prices lower, supporting renewed risk appetite. Small-cap equities benefited significantly, with Information Technology, Industrials, and Health Care leading gains, while Energy declined as crude prices fell. Year to date, the Composite returned +23.7%, slightly ahead of the Russell 2000's +22.6% and well above the HFRI Equity Hedge Index's +9.7%. Additionally, you can review the Portfolio's top 5 holdings to see its best picks for 2026.
In its second-quarter 2026 investor letter, Prosper Stars & Stripes highlighted The Elmet Group Co. (NASDAQ:ELMT). The Elmet Group Co. (NASDAQ:ELMT) manufactures and sells precision-engineered components and high-energy systems for the aerospace, defense and government, industrial, medical, semiconductor and electronics, and energy industries. On September 09, 2026, The Elmet Group Co. (NASDAQ:ELMT) closed at $16.46 per share. Over the past month The Elmet Group Co. (NASDAQ:ELMT) declined 4.02% and its shares lost 15.29% over the past 3 months. The Elmet Group Co. (NASDAQ:ELMT) has a market capitalization of $511.11 million and its stock has traded within a 52-week range of $12.49 to $22.51.
Prosper Stars & Stripes stated the following regarding The Elmet Group Co. (NASDAQ:ELMT) in its Q2 2026 investor letter:
"We are also invested in Applied Aerospace & Defense (AADX) and The Elmet Group Co. (NASDAQ:ELMT). Elmet's critical materials division supplies inputs for the U.S. military supply chain that are essential to production and increasingly must be sourced domestically, steering business towards the company. We believe the building of domestic supply chains can benefit Elmet and drive better-than-forecast earnings growth as they grow organically and deploy their underutilized balance sheet to broaden their businesses."
The Elmet Group Co. (NASDAQ:ELMT) is not on our list of the 40 Most Popular Stocks Among Hedge Funds. As per our database, 19 hedge fund portfolios held The Elmet Group Co. (NASDAQ:ELMT) at the end of the second quarter which was 0 in the previous quarter. While we acknowledge the potential of The Elmet Group Co. (NASDAQ:ELMT) as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring tr

Prosper Stars & Stripes, a long/short equity fund, recently released its second-quarter 2026 investor letter. The letter can be downloaded here. In Q2 2026, the portfolio delivered a strong net return of +30.1% compared to the Russell 2000 Index's +21.5% return and the HFRX Equity Hedge Index's +10.3% return. The long book drove performance, generating a 43.2% gross contribution, while average net exposure remained relatively modest at 47%. U.S. economic growth remained resilient despite inflation concerns, elevated energy prices, and geopolitical uncertainty. Markets rallied sharply after easing U.S.-Iran tensions pushed oil prices lower, supporting renewed risk appetite. Small-cap equities benefited significantly, with Information Technology, Industrials, and Health Care leading gains, while Energy declined as crude prices fell. Year to date, the Composite returned +23.7%, slightly ahead of the Russell 2000's +22.6% and well above the HFRI Equity Hedge Index's +9.7%. Additionally, you can review the Portfolio's top 5 holdings to see its best picks for 2026.
In its second-quarter 2026 investor letter, Prosper Stars & Stripes highlighted Applied Aerospace & Defense, Inc. (NYSE:AADX). Applied Aerospace & Defense, Inc. (NYSE:AADX) designs, engineers, and manufactures integrated aerospace and defense subsystems for **** e and defense applications. On September 09, 2026, Applied Aerospace & Defense, Inc. (NYSE:AADX) closed at $11.94 per share. Over the past month, Applied Aerospace & Defense, Inc. (NYSE:AADX) declined 36.49% and its shares lost 45.95% over the past three months. Applied Aerospace & Defense, Inc. (NYSE:AADX) has a market capitalization of $2.06 billion and its stock has traded within a 52-week range of $11.77 and $24.24.
Prosper Stars & Stripes stated the following regarding Applied Aerospace & Defense, Inc. (NYSE:AADX) in its Q2 2026 investor letter:
"We are also invested in Applied Aerospace & Defense, Inc. (NYSE:AADX) and Elmet Group (ELMT). Applied Aerospace participates in many of the fastest growing programs in defense as a sole sourced, IP-rich component supplier, enabling high (and rising) EBITDA margins. We believe bookings can accelerate and drive revenues, earnings, and the multiple higher."
rommma/Shutterstock.com

#Equity

American Century Investments, an investment management company, released its first-quarter 2026 investor letter for the "American Century Investments Focused Dynamic Growth Fund". The letter can be downloaded here. U.S. stocks advanced sharply with double-digit quarterly gains largely due to robust earnings, resilient economic data, and momentum in AI-related stocks. However, there was a slight pullback in June as momentum waned and investors anticipated potential interest rate hikes by the Federal Reserve. Growth and AI stocks outperformed value stocks, while large-cap companies generally surpassed small- and mid-cap stocks. Underperformance was noted in healthcare and communication services, while industrials, particularly in aerospace and defense, contributed positively to performance. The fund's investor class returned 16.38%, slightly below the Russell 1000 Growth Index's 16.74%. The investment approach focuses on bottom-up financial ****** ysis to identify large-cap companies with long-term earnings growth potential, while aiming to mitigate non-financial risks. Please review the Fund's top five holdings to gain insights into its key selections for 2026.
In its second-quarter 2026 investor letter, American Century Investments Focused Dynamic Growth Fund highlighted Rocket Lab Corporation (NASDAQ:RKLB) as a notable contributor to performance. Rocket Lab Corporation (NASDAQ:RKLB) is an end-to-end ****** e company that provides launch services and ****** e systems solutions. On September 09, 2026, Rocket Lab Corporation (NASDAQ:RKLB) closed at $63.07 per share. Over the past month, Rocket Lab Corporation (NASDAQ:RKLB) declined 21.26%, but its shares are up 30.23% over the past year. Rocket Lab Corporation (NASDAQ:RKLB) has a market capitalization of $40.33 billion, and its stock has traded within a 52-week range of $37.57 to $151.00.
American Century Investments Focused Dynamic Growth Fund stated the following regarding Rocket Lab Corporation (NASDAQ:RKLB) in its Q2 2026 investor letter:
"Rocket Lab Corporation (NASDAQ:RKLB). The commercial ****** e company rallied as record revenue and strong guidance were supported by a large backlog and demand for its launch and ****** e systems businesses. After ****** e Exploration Technologies' June initial public offering drove some volatility, Rocket Lab announced plans to acquire satellite operator Iridium Communications."
Rocket Lab Corporation (NASDAQ:RKLB) is not on our list of the 40 Most Popular Stocks Among Hedge Funds. According to our database, 52 hedge fund portfolios held Rocket Lab Corporation (NASDAQ:RKLB) at the end of the second quarter, compared to 43 in the previous quarter. While we acknowledge the potential of Rocket Lab Corporation (NASDAQ:RKLB) as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the

American Century Investments, an investment management company, released its second-quarter 2026 investor letter for the "American Century Investments Focused Dynamic Growth Fund". The letter can be downloaded here. U.S. stocks advanced sharply with double-digit quarterly gains largely due to robust earnings, resilient economic data, and momentum in AI-related stocks. However, there was a slight pullback in June as momentum waned and investors anticipated potential interest rate hikes by the Federal Reserve. Growth and AI stocks outperformed value stocks, while large-cap companies generally surpassed small- and mid-cap stocks. Underperformance was noted in healthcare and communication services, while industrials, particularly in aerospace and defense, contributed positively to performance. The fund's investor class returned 16.38%, slightly below the Russell 1000 Growth Index's 16.74%. The investment approach focuses on bottom-up financial ***** ysis to identify large-cap companies with long-term earnings growth potential, while aiming to mitigate non-financial risks. Please review the Fund's top five holdings to gain insights into its key selections for 2026.
In its second-quarter 2026 investor letter, American Century Investments Focused Dynamic Growth Fund highlighted Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY). Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY), a biopharmaceutical company that discovers and commercializes therapeutics based on ribonucleic acid interference, detracted from the Fund's performance this quarter. On September 09, 2026, Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) closed at $258.00 per share. Over the past month, Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) returned 13.60%, but its shares are down 44.94% over the past year. Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) has a market capitalization of $34.52 billion, and its stock has traded within a 52-week range of $197.81 to $495.55.
American Century Investments Focused Dynamic Growth Fund stated the following regarding Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) in its Q2 2026 investor letter:
"Stock choices and a sector overweight relative to the benchmark detracted as many biotechnology stocks, including Alnylam Pharmaceuticals and Insmed, underperformed the market. Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY). The biotechnology company's stock underperformed amid concerns of its upcoming late-stage clinical trial readouts despite what we believed was its otherwise strong recent financial performance."

#alny #century

The New York Giants (0-0) will open the regular season against the Dallas Cowboys (0-0) on Sunday Night Football at MetLife Stadium in East Rutherford, New Jersey.
Although apparently healthy, the status of wide receiver Malik Nabers is the injury headliner. He participated in full this week, but neither he nor head coach John Harbaugh has committed to him playing in Week 1. He will be a game-time decision.
"You can never rule out anything," Harbaugh told reporters. "All things are possible."
Ultimately, the Giants made it through the week healthy and will have their full complement of players available on Sunday, Nabers notwithstanding. For now.
Full injury reports for both the Giants and Cowboys can be found below:

#week #cowboys #york